Compare BHVN & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHVN | AGIO |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2022 | 2013 |
| Metric | BHVN | AGIO |
|---|---|---|
| Price | $14.53 | $33.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 8 |
| Target Price | $29.08 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.8M | 1.2M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 26.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | N/A | $170.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.48 | $22.24 |
| 52 Week High | $18.57 | $46.00 |
| Indicator | BHVN | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 47.68 |
| Support Level | $13.84 | $26.71 |
| Resistance Level | $15.79 | $36.07 |
| Average True Range (ATR) | 0.65 | 1.69 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 75.92 | 64.17 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.